TQ Therapeutics
Pre-clinicalOur CELLfinity platform is delivering safe in vivo cell & gene therapies that is based on our proprietary EXiVO approach, without abandoning the advantages of autologous cell therapy
Founded
2019
Focus
OncologyAntibodies
About
Our CELLfinity platform is delivering safe in vivo cell & gene therapies that is based on our proprietary EXiVO approach, without abandoning the advantages of autologous cell therapy
Funding History
1Total raised: $5M
Seed$5MHigh-Tech GründerfondsSep 15, 2021
Company Info
TypePrivate
Founded2019
LocationMunich, Germany
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile